Research
Cellular Origins partners with ScaleReady to simplify, standardise, and automate cell therapy manufacturing
Cellular Origins, a TTP Company focused on enabling scalable, cost-effective and efficient manufacture of cell and gene therapies (CGTs), announces collaborative partnership with ScaleReady, a joint venture between Bio-Techne, Fresenius Kabi and Wilson Wolf that brings together process ...
NIHR BioResource and REPROCELL – Establishing a research stem cell bank for inherited genetic disorders
The NIHR BioResource and three of our rare disease volunteers have supported a study that aims to aid in the discovery and development of new drugs and potential treatments for many common and rare diseases. ...
NIHR BioResource Scientific Conference 2023
The first NIHR BioResource Scientific Conference is aimed at academic, industry and NHS researchers who would benefit from access to clinical and genetic data, biosamples, and/or the ability to identify and recall specific individuals based on genotype and/or phenotype. ...
2023 Annual Visitor Attraction Website Report Survey launched
Rubber Cheese, in partnership with Convious, is proud to announce the launch of the 2023 Annual Visitor Attraction Website Report Survey to help attractions improve their digital infrastructure and enhance the visitor experience, moving from clicks to conversions. ...
Dr Cathy Tralau-Stewart appointed Executive Director of the Milner Therapeutics Institute
The Milner Therapeutics Institute are delighted to welcome Dr Cathy Tralau-Stewart as our new Executive Director. ...
Cambridge AI Club - April Theme - "Large language models for biomedical data"
The AI Club is a new initiative to bring together the Biomedical AI and Machine Learning community in Cambridge, to discuss common themes and explore different topics and methodologies. ...
Webinar: Integrated prediction of phase I and II metabolism
Want to avoid late-stage failure of your drug candidates? Understanding the metabolism of your compounds is crucial. On 24 May, join Optibrium CEO Matt Segall and Principal Scientist Mario Öeren to explore groundbreaking new quantum mechanics and machine learning models which...
US patent granted protecting proprietary formulations of monoclonal antibodies
Endorses potential of proprietary Arestat™ platform technology to invent novel, enhanced therapeutics in $210 billion monoclonal antibody market Further strengthens Group’s extensive patent portfolio Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical group advancing today’...
Consumer confidence in Visitor Attractions and the opportunities open to the sector
According to research carried out by Tourism Insight specialists the BVA BDRC, attitudes to spending are improving, but the public remain concerned about their finances and are making cut backs. ...
Maxion Therapeutics awarded £2 million Innovate UK funding to develop ion channel antibodies for “hard-to-treat" autoimmune diseases
Biotechnology company Maxion Therapeutics announces it has been awarded a prestigious GBP £2 million grant from Innovate UK, as part of its Biomedical Catalyst 2022 Round 2: Industry-led R&D funding competition. ...